145 related articles for article (PubMed ID: 18993071)
1. Orally bioavailable prodrugs of a BCS class 2 molecule, an inhibitor of HIV-1 reverse transcriptase.
Elworthy TR; Dunn JP; Hogg JH; Lam G; Saito YD; Silva TM; Stefanidis D; Woroniecki W; Zhornisky E; Zhou AS; Klumpp K
Bioorg Med Chem Lett; 2008 Dec; 18(24):6344-7. PubMed ID: 18993071
[TBL] [Abstract][Full Text] [Related]
2. 1,2,3-Thiadiazole thioacetanilides as a novel class of potent HIV-1 non-nucleoside reverse transcriptase inhibitors.
Zhan P; Liu X; Cao Y; Wang Y; Pannecouque C; De Clercq E
Bioorg Med Chem Lett; 2008 Oct; 18(20):5368-71. PubMed ID: 18824350
[TBL] [Abstract][Full Text] [Related]
3. Development of water-soluble prodrugs of the HIV-1 protease inhibitor KNI-727: importance of the conversion time for higher gastrointestinal absorption of prodrugs based on spontaneous chemical cleavage.
Sohma Y; Hayashi Y; Ito T; Matsumoto H; Kimura T; Kiso Y
J Med Chem; 2003 Sep; 46(19):4124-35. PubMed ID: 12954064
[TBL] [Abstract][Full Text] [Related]
4. Discovery of 3-{5-[(6-amino-1H-pyrazolo[3,4-b]pyridine-3-yl)methoxy]-2-chlorophenoxy}-5-chlorobenzonitrile (MK-4965): a potent, orally bioavailable HIV-1 non-nucleoside reverse transcriptase inhibitor with improved potency against key mutant viruses.
Tucker TJ; Sisko JT; Tynebor RM; Williams TM; Felock PJ; Flynn JA; Lai MT; Liang Y; McGaughey G; Liu M; Miller M; Moyer G; Munshi V; Perlow-Poehnelt R; Prasad S; Reid JC; Sanchez R; Torrent M; Vacca JP; Wan BL; Yan Y
J Med Chem; 2008 Oct; 51(20):6503-11. PubMed ID: 18826204
[TBL] [Abstract][Full Text] [Related]
5. [d4U]-butyne-[HI-236] as a non-cleavable, bifunctional NRTI/NNRTI HIV-1 reverse-transcriptase inhibitor.
Hunter R; Muhanji CI; Hale I; Bailey CM; Basavapathruni A; Anderson KS
Bioorg Med Chem Lett; 2007 May; 17(9):2614-7. PubMed ID: 17317163
[TBL] [Abstract][Full Text] [Related]
6. Water-soluble prodrugs of the human immunodeficiency virus protease inhibitors lopinavir and ritonavir.
DeGoey DA; Grampovnik DJ; Flosi WJ; Marsh KC; Wang XC; Klein LL; McDaniel KF; Liu Y; Long MA; Kati WM; Molla A; Kempf DJ
J Med Chem; 2009 May; 52(9):2964-70. PubMed ID: 19348416
[TBL] [Abstract][Full Text] [Related]
7. Design of annulated pyrazoles as inhibitors of HIV-1 reverse transcriptase.
Sweeney ZK; Harris SF; Arora SF; Javanbakht H; Li Y; Fretland J; Davidson JP; Billedeau JR; Gleason SK; Hirschfeld D; Kennedy-Smith JJ; Mirzadegan T; Roetz R; Smith M; Sperry S; Suh JM; Wu J; Tsing S; Villaseñor AG; Paul A; Su G; Heilek G; Hang JQ; Zhou AS; Jernelius JA; Zhang FJ; Klumpp K
J Med Chem; 2008 Dec; 51(23):7449-58. PubMed ID: 19007201
[TBL] [Abstract][Full Text] [Related]
8. Optimization of 5-aryloxyimidazole non-nucleoside reverse transcriptase inhibitors.
Jones LH; Allan G; Corbau R; Hay D; Middleton DS; Mowbray CE; Newman SD; Perros M; Randall A; Vuong H; Webster R; Westby M; Williams D
ChemMedChem; 2008 Nov; 3(11):1756-62. PubMed ID: 18855969
[TBL] [Abstract][Full Text] [Related]
9. Design, synthesis, and anti-HIV activity of 4'-modified carbocyclic nucleoside phosphonate reverse transcriptase inhibitors.
Boojamra CG; Parrish JP; Sperandio D; Gao Y; Petrakovsky OV; Lee SK; Markevitch DY; Vela JE; Laflamme G; Chen JM; Ray AS; Barron AC; Sparacino ML; Desai MC; Kim CU; Cihlar T; Mackman RL
Bioorg Med Chem; 2009 Feb; 17(4):1739-46. PubMed ID: 19179082
[TBL] [Abstract][Full Text] [Related]
10. Discovery and optimization of pyridazinone non-nucleoside inhibitors of HIV-1 reverse transcriptase.
Sweeney ZK; Dunn JP; Li Y; Heilek G; Dunten P; Elworthy TR; Han X; Harris SF; Hirschfeld DR; Hogg JH; Huber W; Kaiser AC; Kertesz DJ; Kim W; Mirzadegan T; Roepel MG; Saito YD; Silva TM; Swallow S; Tracy JL; Villasenor A; Vora H; Zhou AS; Klumpp K
Bioorg Med Chem Lett; 2008 Aug; 18(15):4352-4. PubMed ID: 18632268
[TBL] [Abstract][Full Text] [Related]
11. Design, synthesis and in vitro/in vivo evaluation of orally bioavailable prodrugs of a catechol-O-methyltransferase inhibitor.
Rautio J; Leppänen J; Lehtonen M; Laine K; Koskinen M; Pystynen J; Savolainen J; Sairanen M
Bioorg Med Chem Lett; 2010 Apr; 20(8):2614-6. PubMed ID: 20231095
[TBL] [Abstract][Full Text] [Related]
12. Orally active factor Xa inhibitors: investigation of a novel series of 3-amidinophenylsulfonamide derivatives using an amidoxime prodrug strategy.
Uchida M; Okazaki K; Mukaiyama H; Isawa H; Kobayashi H; Shiohara H; Muranaka H; Kai Y; Kikuchi N; Takeuchi H; Yokoyama K; Tsuji E; Ozawa T; Hoyano Y; Koizumi T; Misawa K; Hara K; Nakano S; Murakami Y; Okuno H
Bioorg Med Chem Lett; 2008 Aug; 18(16):4682-7. PubMed ID: 18667303
[TBL] [Abstract][Full Text] [Related]
13. Design, synthesis, and evaluation of orally active inhibitors of plasminogen activator inhibitor-1 (PAI-1) production.
Miyazaki H; Ogiku T; Sai H; Ohmizu H; Murakami J; Ohtani A
Bioorg Med Chem Lett; 2008 Dec; 18(24):6419-22. PubMed ID: 18993062
[TBL] [Abstract][Full Text] [Related]
14. Aminocarbonyloxymethyl ester prodrugs of flufenamic acid and diclofenac: suppressing the rearrangement pathway in aqueous media.
Ribeiro L; Silva N; Iley J; Rautio J; Järvinen T; Mota-Filipe H; Moreira R; Mendes E
Arch Pharm (Weinheim); 2007 Jan; 340(1):32-40. PubMed ID: 17206608
[TBL] [Abstract][Full Text] [Related]
15. Prodrug strategies to overcome poor water solubility.
Stella VJ; Nti-Addae KW
Adv Drug Deliv Rev; 2007 Jul; 59(7):677-94. PubMed ID: 17628203
[TBL] [Abstract][Full Text] [Related]
16. Powder for reconstitution of the anti-HIV-1 drug TMC278 - Formulation development, stability and animal studies.
Van Gyseghem E; Pendela M; Baert L; Rosier J; Van 't Klooster G; De Man H; Bouche MP; Schueller L; Van Remoortere P; Wigerinck P; Adams E; Hoogmartens J; Van den Mooter G
Eur J Pharm Biopharm; 2008 Nov; 70(3):853-60. PubMed ID: 18657611
[TBL] [Abstract][Full Text] [Related]
17. Diphenyl ether non-nucleoside reverse transcriptase inhibitors with excellent potency against resistant mutant viruses and promising pharmacokinetic properties.
Sweeney ZK; Kennedy-Smith JJ; Wu J; Arora N; Billedeau JR; Davidson JP; Fretland J; Hang JQ; Heilek GM; Harris SF; Hirschfeld D; Inbar P; Javanbakht H; Jernelius JA; Jin Q; Li Y; Liang W; Roetz R; Sarma K; Smith M; Stefanidis D; Su G; Suh JM; Villaseñor AG; Welch M; Zhang FJ; Klumpp K
ChemMedChem; 2009 Jan; 4(1):88-99. PubMed ID: 19006142
[TBL] [Abstract][Full Text] [Related]
18. Design, synthesis, and biological evaluation of a series of 2-hydroxyisoquinoline-1,3(2H,4H)-diones as dual inhibitors of human immunodeficiency virus type 1 integrase and the reverse transcriptase RNase H domain.
Billamboz M; Bailly F; Barreca ML; De Luca L; Mouscadet JF; Calmels C; Andréola ML; Witvrouw M; Christ F; Debyser Z; Cotelle P
J Med Chem; 2008 Dec; 51(24):7717-30. PubMed ID: 19053754
[TBL] [Abstract][Full Text] [Related]
19. Orally bioavailable isothioureas block function of the chemokine receptor CXCR4 in vitro and in vivo.
Thoma G; Streiff MB; Kovarik J; Glickman F; Wagner T; Beerli C; Zerwes HG
J Med Chem; 2008 Dec; 51(24):7915-20. PubMed ID: 19053768
[TBL] [Abstract][Full Text] [Related]
20. 10-Hydroxy-7,8-dihydropyrazino[1',2':1,5]pyrrolo[2,3-d]pyridazine-1,9(2H,6H)-diones: potent, orally bioavailable HIV-1 integrase strand-transfer inhibitors with activity against integrase mutants.
Wiscount CM; Williams PD; Tran LO; Embrey MW; Fisher TE; Sherman V; Homnick CF; Donnette Staas D; Lyle TA; Wai JS; Vacca JP; Wang Z; Felock PJ; Stillmock KA; Witmer MV; Miller MD; Hazuda DJ; Day AM; Gabryelski LJ; Ecto LT; Schleif WA; DiStefano DJ; Kochansky CJ; Anari MR
Bioorg Med Chem Lett; 2008 Aug; 18(16):4581-3. PubMed ID: 18657970
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
